EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 870 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR How I Learned to Cope With Survivor’s Guilt After Cancer January 27, 2021 Young Breast Cancer Survivor Killed in Hit and Run Crash Weeks... August 25, 2021 Cancer and Climate Change: The Health Threats of Unnatural Disasters April 5, 2023 Proton and Intensity-Modulated Radiation Therapy for Oropharyngeal Cancer Show Similar Late Effects, QoL,... April 2, 2026 Load more HOT NEWS Withdrawal of the Application to Change the EMA Marketing Authorisation for... FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... A Subgroup of Patients with a Very Poor Prognosis Diffuse Intrinsic...
